Antidepressant fluoxetine found ineffective for early COVID-19 treatment
Sanatate
By Tarun Sai Lomte Reviewed by Lily Ramsey, LLM Jan 22 2025 Evidence shows weak antiviral activity and no improvement in symptom outcomes. Study: Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV) . Image Credit: luchschenF/Shutterstock.com In a recent study published in eClinicalMedicine , researchers characterized the antiviral activity of a selective serotonin reuptake inhibitor (SSRI), fluoxetine, in
astăzi